Source author record

Stephen Quake

Stephen Quake appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record

Catalog footprint

What is connected

2works
5topics
4close collaborators

Actions

Connect this record

Log in to claim

Research graph

See the researcher in context

Open full explorer

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

2 published item(s)

preprint2026arXiv

Informational blueprints reveal condition-dependent gene regulatory architectures

While coding regions in the genome have a direct interpretation in terms of protein products, significant fractions are non-coding and yet control essential biological functions. Unlike the genetic code, there is no "lookup table" that identifies where regulatory proteins, known as transcription factors (TFs), bind. Here, we extract these binding sites by distilling sequences of nucleotide letters into collective coordinates (hyperletters) representing the binding sites that are active under specific environmental conditions. Going beyond local information footprints between individual bases and expression levels, our $\textit{information blueprint}$ algorithm compresses the global information by optimising filters that simultaneously scan an entire promoter sequence. Inspired by renormalisation-group techniques, we identify TF binding sites as coarse-grained variables combining groups of correlated mutations with the highest collective impact on gene expression. We validate our approach on experimental data for $\textit{E. coli}$ and discover novel regulatory elements illustrating its deployment at scale across growth conditions.

preprint2013arXiv

Designing the statistically optimal drug for cancer therapy

Cancer and healthy cells have distinct distributions of molecular properties and thus respond differently to drugs. Cancer drugs ideally kill cancer cells while limiting harm to healthy cells. However, the inherent variance among cells in both cancer and healthy cell populations increases the difficulty of selective drug action. Here we propose a classification framework based on the idea that an ideal cancer drug should maximally discriminate between cancer and healthy cells. We first explore how molecular markers can be used to discriminate cancer cells from healthy cells on a single cell basis, and then how the effects of drugs are statistically predicted by these molecular markers. We then combine these two ideas to show how to optimally match drugs to tumor cells. We find that expression levels of a handful of genes suffice to discriminate well between individual cells in cancer and healthy tissue. We also find that gene expression predicts the efficacy of cancer drugs, suggesting that the cancer drugs act as classifiers using gene profiles. In agreement with our first finding, a small number of genes predict drug efficacy well. Finally, we formulate a framework that defines an optimal drug, and predicts drug cocktails that may target cancer more accurately than the individual drugs alone. Conceptualizing cancer drugs as solving a discrimination problem in the high-dimensional space of molecular markers promises to inform the design of new cancer drugs and drug cocktails.